Erasmus School of Health Policy & Management
Visiting fellow | Health Technology Assessment (HTA)
- vangils@eshpm.eur.nl
More information
Work
- Renaud J.S.D. Heine, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils & Carin A. Uyl-de Groot (2024) - Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands - Value in Health, 27 (10), 1367-1372 - doi: 10.1016/j.jval.2024.06.003 - [link]
- D. A. Young-Afat, , C. H. van Gils, H. J.G.D. van den Bongard, H. M. Verkooijen, S. A. Gernaat, M. L. Gregorowitsch, A. M. May, P. H. Peeters, C. C. van der Pol, A. J. Witkamp, R. M. Pijnappel, R. M. Bijlsma, W. Maarse, M. G. Ausems, P. J. van Diest, E. van der Wall, T. van Dalen, I. P. Burgmans, M. A. de Roos, R. C. van Doorn, I. O. Baas, B. van Ooijen & R. Koelemij (2017) - The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results - Breast Cancer Research and Treatment, 164 (2), 445-450 - doi: 10.1007/s10549-017-4242-4 - [link]
- L Mohseninejad, Chantal van Gils, Carin Uyl - de Groot, E Buskens & TL (Talitha) Feenstra (2015) - Evaluation of Patient Registries Supporting Reimbursement Decisions: The Case of Oxaliplatin for Treatment of Stage III Colon Cancer - Value in Health, 18, 84-90 - doi: 10.1016/j.jval.2014.10.008 - [link]
- Lucas Goossens, Ken Redekop & Chantal van Gils (2015) - Noncollapsibility and Censoring: What's the Bias in Estimating Effects on Survival? - Epidemiology, 26 (1), e1-e2 - doi: 10.1097/EDE.0000000000000197
- Chantal van Gils, Saskia de Groot, Siok Swan Tan, Ken Redekop, M Koopman, CJ Punt & Carin Uyl - de Groot (2014) - Real-world resource use and costs of adjuvant treatment for stage III colon cancer - European Journal of Cancer Care, 24 (3), 321-332 - doi: 10.1111/ecc.12154 - [link]
- Naomi Linden, Chantal van Gils, CP Pescott, J Buter, MR Vergeer & Carin Uyl - de Groot (2014) - Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck - European Archives of Oto-Rhino-Laryngology, 272 (8), 2007-2016 - doi: 10.1007/s00405-014-3106-3
- Chantal van Gils (2013) - Real-world cost-effectiveness - [link]
- Naomi Linden, Chantal van Gils, CP Pescott, J Buter & Carin Uyl - de Groot (2013) - Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results - European Archives of Oto-Rhino-Laryngology, 271 (6), 1673-1678 - doi: 10.1007/s00405-013-2646-2 - [link]
- Chantal van Gils, Saskia de Groot, Ken Redekop, M Koopman, CJA Punt & Carin Uyl - de Groot (2013) - Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence - Pharmacoeconomics (Print), 31 (8), 703-718 - doi: 10.1007/s40273-013-0061-6 - [link]
- Margreet Franken, Chantal van Gils, JG (Jennifer G.) Gaultney, GO Delwel, W Goettsch, PC Huijgens, Adri Steenhoek, CJA Punt, M Koopman, Ken Redekop & Carin Uyl - de Groot (2013) - Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands - European Journal of Cancer, 49, 8-16 - doi: 10.1016/j.ejca.2012.06.010 - [link]
- Chantal van Gils, M Koopman, L (Linda) Mol, Ken Redekop, Carin Uyl - de Groot & CJA Punt (2012) - Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands - Acta Oncologica, 51, 57-64 - doi: 10.3109/0284186X.2011.633930 - [link]
- Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, Siok Swan Tan, Chantal van Gils, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Uyl - de Groot (2012) - Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma - [link]
- Siok Swan Tan, Chantal van Gils, Margreet Franken, Leona Hakkaart - van Roijen & Carin Uyl - de Groot (2010) - The Unit Costs of Inpatient Hospital Days, Outpatient Visits and Daycare Treatments in the Fields of Oncology and Hematology - Value in Health, 13 (6), 712-719 - doi: 10.1111/j.1524-4733.2010.00740.x - [link]
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2024
- Course Code
- GW4555M
Master Thesis HE
- Year Level
- master, master
- Year
- 2024
- Course Code
- GW4592M
